NAS
PCRX icon

Nykredit A/S’s Pacira BioSciences PCRX Stock Holding History

Nykredit A/S’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$19.1K Buy
+751
New +$17.8K ﹤0.01% 1746

Other funds holding PCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DPCM
Doma Perpetual Capital Management Miami, Florida $431M AUM 13.21% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Nykredit A/S's PCRX Position: Q2 2026 in Review

Nykredit A/S opened a new position in Pacira BioSciences (PCRX) in Q2 2026: 751 shares worth $19.1K. The stake represents ﹤0.01% of the portfolio and ranks #1746 among its holdings.

183 funds tracked by Wall St. Rank hold PCRX as of Q2 2026.

  • Nykredit A/S held 751 shares of Pacira BioSciences worth $19.1K as of Q2 2026.
  • Pacira BioSciences was a new Nykredit A/S position in Q2 2026.
  • Pacira BioSciences made up ﹤0.01% of Nykredit A/S's portfolio in Q2 2026, its #1746 holding.
  • 183 funds tracked by Wall St. Rank held Pacira BioSciences as of Q2 2026.

Based on Nykredit A/S's 13F filing for Q2 2026, filed 13 Aug 2026.